Skip to main content

New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)


ATC Code: G04BD (incomplete)
Wikipedia: Mirabegron


On June 28 2012, the FDA approved Mirabegron (tradename: Myrbetriq; Research Code: YM-178), a novel, first-in-class selective β3-adrenergic receptor agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. OAB syndrome is a urological condiction defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urge urinary incontinence, in the absence of urinary tract infection or other obvious pathology. Mirabegron acts by relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of β3-receptor which in turn increases bladder capacity.

Other treatments for OAB are already in the market and these include treatments with antimuscarinic drugs, such as Flavoxate (approved in 1970; tradename: Urispas; ChEMBL: CHEMBL1493), Oxybutynin (approved in 1975, tradenames: Ditropan, Ditropan XL, Oxytrol, Gelnique, Anturol; ChEMBL: CHEMBL1231), Tolterodine (approved in 1998; tradenames: Detrol, Detrol LA; ChEMBL: CHEMBL1382), Trospium (approved in 2004; tradenames: Santura, Santura XR; ChEMBL: CHEMBL1201344), Solifenacin (approved in 2004; tradenames: Vesicare; ChEMBL: CHEMBL1200803), Darifenacin (approved in 2004; tradenames: Enablex; ChEMBL: CHEMBL1346) and Fesoterodine (approved in 2008; tradenames: Toviaz; ChEMBL: CHEMBL1201764). While these drugs act by inhibiting the muscarinic action of acethylcholine, Mirabegron represents the first β3-receptor agonist to ever reach the market.

β3-receptor (ChEMBL: CHEMBL246; Uniprot: P13945) is a 408 amino-acid long G protein-coupled receptor (GPCR), belonging to Rhodopsin family (PFAM: PF00001; subfamily A17). Crystal structures of the closely related β1- and β2-receptors are known and act as good frameworks for understanding the mode of action of Mirabegron.

>ADRB3_HUMAN Beta-3 adrenergic receptor
MAPWPHENSSLAPWPDLPTLAPNTANTSGLPGVPWEAALAGALLALAVLATVGGNLLVIV
AIAWTPRLQTMTNVFVTSLAAADLVMGLLVVPPAATLALTGHWPLGATGCELWTSVDVLC
VTASIETLCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIMSQWWRV
GADAEAQRCHSNPRCCAFASNMPYVLLSSSVSFYLPLLVMLFVYARVFVVATRQLRLLRG
ELGRFPPEESPPAPSRSLAPAPVGTCAPPEGVPACGRRPARLLPLREHRALCTLGLIMGT
FTLCWLPFFLANVLRALGGPSLVPGPAFLALNWLGYANSAFNPLIYCRSPDFRSAFRRLL
CRCGRRLPPEPCAAARPALFPSGVPAARSSPAQPRLCQRLDGASWGVS


Mirabegron is a synthetic chiral small-molecule, with a molecular weight of 396.51 Da, a AlogP of 2.26, 4 hydrogen bond donors and 5 hydrogen bond acceptors, and thus fully rule-of-five compliant. (IUPAC: 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide; Canonical Smiles: C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O; InChI: InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1)

The recommended starting dosage of Mirabegron is 25 mg once daily, with or without food, and is effective for 8 weeks. Depending individual patient efficacy and tolerability, the dose may be increased to 50 mg once daily.

Mirabegron has a bioavalibity of 29% at a dose of 25 mg, which increases to 35% at a dose of 50 mg, a volume of distribution (Vd) of approximately 1670 L and a moderate plasma protein binding of ca. 71%. Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, glucuronidation and amide hydrolyis. Studies have suggested that although CYP3A4 and CYP2D6 isoenzymes play a role in the oxidative metabolism of Mirabegron, this is a limited role in the overall elimination. In addition to these isoenzymes, the metabolism of Mirabegron may also involve butylcholinesterase, uridine diphospho-glucuronosyltransferases and alcohol dehydrogenase. Two major inactive metabolites were observed in human plasma and these represent 16% and 11% of the total exposure. Mirabegron total clearance (CLtot) from plasma is ca. 57 L/h, with a terminal half-life of approximately of 50 hours. Renal clearance (CLR) is approximately 13 L/h, which corresponds to nearly 25% of CLtot. The urinary elimination of unchanged Mirabegron is dose-dependent and ranges from ca. 6% after a daily dose of 25 mg to 12.2% after a daily dose of 100 mg.

The license holder is Astellas Pharma Inc. and the full prescribing information of Mirabegron can be found here.

Comments

Popular posts from this blog

RDKit, C++ and Jupyter Notebook

Fancy playing with RDKit C++ API without needing to set up a C++ project and compile it? But wait... isn't C++ a compiled programming language? How this can be even possible?

Thanks to Cling (CERN's C++ interpreter) and xeus-cling jupyter kernel is possible to use C++ as an intepreted language inside a jupyter notebook!

We prepared a simple notebook showing few examples of RDKit functionalities and a docker image in case you want to run it.

With the single requirement of docker being installed in your computer you'll be able to easily run the examples following the three steps below:
docker pull eloyfelix/rdkit_jupyter_clingdocker run -d -p 9999:9999 eloyfelix/rdkit_jupyter_clingopen http://localhost:9999/notebooks/rdkit_cling.ipynb in a browser


ChEMBL 25 and new web interface released

We are pleased to announce the release of ChEMBL 25 and our new web interface. This version of the database, prepared on 10/12/2018 contains:

2,335,417 compound records1,879,206 compounds (of which 1,870,461 have mol files)15,504,603 activities1,125,387 assays12,482 targets72,271 documents

Data can be downloaded from the ChEMBL ftp site: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25

Please see ChEMBL_25 release notes for full details of all changes in this release: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25/chembl_25_release_notes.txt


DATA CHANGES SINCE THE LAST RELEASE

# Deposited Data Sets:

Kuster Lab Chemical Proteomics Drug Profiling (src_id = 48, Document ChEMBL_ID = CHEMBL3991601):
Data have been included from the publication: The target landscape of clinical kinase drugs. Klaeger S, Heinzlmeir S and Wilhelm M et al (2017), Science, 358-6367 (https://doi.org/10.1126/science.aan4368)

# In Vivo Assay Classification:

A classification…

FPSim2, a simple Python3 molecular similarity tool

FPSim2 is a new tool for fast similarity search on big compound datasets (>100 million) being developed at ChEMBL. We started developing it as we needed a Python3 library able to run either in memory or out-of-core fast similarity searches on such dataset sizes.

It's written in Python/C++ and features:
A fast population count algorithm (builtin-popcnt-unrolled) from https://github.com/WojciechMula/sse-popcount using SIMD instructions.Bounds for sub-linear speed-ups from 10.1021/ci600358fA compressed file format with optimised read speed based in PyTables and BLOSCUse of multiple cores in a single search In memory and on disk search modesSimple and easy to use
Source code is available on github and Conda packages are also available for either mac or linux. To install it type:

conda install rdkit -c rdkitconda install fpsim2 -c efelix
Try it with docker (much better performance than binder):

    docker pull eloyfelix/fpsim2    docker run -p 9999:9999 eloyfelix/fpsim2    open http:/…

2019 and ChEMBL – News, jobs and birthdays

Happy New Year from the ChEMBL Group to all our users and collaborators. 
Firstly, do you want a new challenge in 2019?  If so, we have a position for a bioinformatician in the ChEMBL Team to develop pipelines for identifying links between therapeutic targets, drugs and diseases.  You will be based in the ChEMBL team but also work in collaboration with the exciting Open Targets initiative.  More details can be found here(closing date 24thJanuary). 
In case you missed it, we published a paper at the end of last on the latest developments of the ChEMBL database “ChEMBL: towards direct deposition of bioassay data”. You can read it here.  Highlights include bioactivity data from patents, human pharmacokinetic data from prescribing information, deposited data from neglected disease screening and data from the IMI funded K4DD project.  We have also added a lot of new annotations on the therapeutic targets and indications for clinical candidates and marketed drugs to ChEMBL.  Importantly we ha…

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications:

- Deep Learning as an Opportunity in VirtualScreening
- Massively Multitask Networks for Drug Discovery
- Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set

But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach.

So, having a set of activities relating targets and molecules we can train a single neural network as a binary multi-label classifier that will output the probability of activity/inactivity for each of the targets (tasks) for a given query molecule…